In the same GBM tumor model, LIGHT-VTP treatment in combination with anti-VEGF and anti-PD-L1 is even more effective than agonistic LTβR antibodies, and generates an abundance of intratumoral HEV+ TLS and granzyme B+ (GrzB) CD8+ effector T cells (116). This evidence concerns the gene VEGFA and glioblastoma.